Eslicarbazepine acetate add-on for drug-resistant partial epilepsy

doi:10.1002/14651858.CD008907.pub2

科研成果详情

题名	Eslicarbazepine acetate add-on for drug-resistant partial epilepsy
作者	Chang, Xian-Chao 2; Yuan, Hai 3; Wang, Yi4; Xu, Hui-Qin1; Zheng, Rong-Yuan1
发表日期	2011-12-31
发表期刊	COCHRANE DATABASE OF SYSTEMATIC REVIEWS 影响因子和分区
语种	英语
原始文献类型	Review
其他关键词	PARTIAL-ONSET SEIZURES ; ADJUNCTIVE TREATMENT ; DOUBLE-BLIND ; EFFICACY ; ADULTS ; SAFETY ; TRIAL
摘要	Background The majority of people with epilepsy will have a good prognosis, but up to 30% of patients will continue to have seizures despite several regimens of antiepileptic drugs. In this review we summarized the current evidence regarding eslicarbazepine acetate (ESL) when used as an add-on treatment for drug-resistant partial epilepsy. Objectives To evaluate the efficacy and tolerability of ESL when used as an add-on treatment for people with drug-resistant partial epilepsy. Search methods We searched the Cochrane Epilepsy Group Specialized Register (3 November 2011), The Cochrane Central Register of Controlled Trials (CENTRAL issue 4 of 4, The Cochrane Library 2011), and MEDLINE (1948 to October week 4, 2011). There were no language restrictions. We reviewed the reference lists of retrieved studies to search for additional reports of relevant studies. We also contacted the manufacturers of ESL and experts in the field for information about any unpublished or ongoing studies. Selection criteria Randomized placebo controlled double-blind add-on trials of ESL in people with drug-resistant partial epilepsy. Data collection and analysis Two review authors independently selected trials for inclusion and extracted data. Outcomes investigated included 50% or greater reduction in seizure frequency; seizure freedom; treatment withdrawal; adverse effects; and drug interactions. Primary analyses were by intention to treat. The dose response relationship was evaluated in regression models. Main results Four trials (1146 participants) were included; all studies were funded by BIAL. The overall relative risk (RR) with 95% confidence interval (CIs) for 50% or greater reduction in seizure frequency outcome was 1.86 (95% CI 1.46 to 2.36). Dose regression analysis showed evidence that ESL reduced seizure frequency with an increase in efficacy with increasing doses of ESL. ESL was significantly associated with seizure freedom (RR 3.04, 95% CI 1.44 to 6.42). Participants seemed more likely (albeit not significantly) to have ESL withdrawn for adverse effects (RR 2.26, 95% CI 0.98 to 5.21) but not for any reason (RR 1.07, 95% CI 0.73 to 1.57). The following adverse effects were significantly associated with ESL: dizziness (RR 3.09, 99% CI 1.76 to 5.43); nausea (RR 3.06, 99% CI 1.07 to 8.74); and diplopia (RR 3.73, 99% CI 1.19 to 11.64). Authors' conclusions Eslicarbazepine acetate reduces seizure frequency when used as an add-on treatment for people with drug-resistant partial epilepsy. The trials included in this review were of short-term duration and focused on adults.
资助项目	Zhejiang Key Subject (Pharmacology and Biochemical Pharmaceutics), China
出版者	WILEY
出版地	HOBOKEN
ISSN	1469-493X
EISSN	1361-6137
期号	12
DOI	10.1002/14651858.CD008907.pub2
页数	40
WOS类目	Medicine, General & Internal
WOS研究方向	General & Internal Medicine
WOS记录号	WOS:000300937600082
收录类别	SCIE
PubMed ID	22161441
通讯作者地址	[Zheng, Rong-Yuan]Wenzhou Med Coll, Affiliated Hosp 1, Dept Neurol, 2 Fuxue Lane, Wenzhou 325000, Zhejiang, Peoples R China.
TOP期刊	TOP期刊
引用统计	被引频次：7[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/16390
专题	第一临床医学院（信息与工程学院）、附属第一医院_内科学_神经内科公共卫生学院附属第二医院附属第一医院第二临床医学院、附属第二医院、育英儿童医院仁济学院_环境与公共卫生学部附属第二医院_康复科
通讯作者	Zheng, Rong-Yuan
作者单位	1.Wenzhou Med Coll, Affiliated Hosp 1, Dept Neurol, Wenzhou 325000, Zhejiang, Peoples R China; 2.Ningbo 2 Hosp, Dept Neurol, Ningbo, Zhejiang, Peoples R China; 3.Wenzhou Med Coll, Affiliated Hosp 2, Dept Rehabil, Wenzhou 325000, Zhejiang, Peoples R China; 4.Wenzhou Med Coll, Sch Environm & Publ Hlth, Wenzhou 325000, Zhejiang, Peoples R China
通讯作者单位	附属第一医院
推荐引用方式 GB/T 7714	Chang, Xian-Chao,Yuan, Hai,Wang, Yi,et al. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS,2011(12).
APA	Chang, Xian-Chao, Yuan, Hai, Wang, Yi, Xu, Hui-Qin, & Zheng, Rong-Yuan. (2011). Eslicarbazepine acetate add-on for drug-resistant partial epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS(12).
MLA	Chang, Xian-Chao,et al."Eslicarbazepine acetate add-on for drug-resistant partial epilepsy".COCHRANE DATABASE OF SYSTEMATIC REVIEWS .12(2011).